Adial Pharmaceuticals, Inc. (ADIL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Adial Pharmaceuticals reported revenue of $0. Net income was -$8.0M, or -$11.93 per diluted share. Operating activities generated -$6.5M of cash. At fiscal year end, Adial Pharmaceuticals held $6.7M in total assets against $1.4M in total liabilities, including $5.9M of cash and equivalents.
Open the full interactive Adial Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Adial Pharmaceuticals Key Stats
| Share Price | $3.29 |
|---|---|
| Market Cap | $15.2M |
| 52-Week Range | $1.36 – $9.75 |
| Shares Outstanding | 4.6 million (basic, 2026 Q2) |
Adial Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Goods Sold | — | — | $550,000 | — | — | — |
| Gross Profit | — | — | -$550,000 | — | — | — |
| Operating Income | -$10.9M | -$19.3M | -$13.3M | -$6.9M | -$8.3M | -$7.8M |
| Pre-Tax Income | -$10.9M | -$19.5M | -$12.7M | -$7.0M | -$13.2M | -$8.0M |
| Income Tax | — | -$94,077 | -$502 | -$1.9M | — | — |
| Net Income | -$10.9M | -$19.4M | -$12.7M | -$5.1M | -$13.2M | -$8.0M |
| Diluted EPS | -$543.75 | -$650.00 | -$318.75 | -$90.00 | -$68.00 | -$11.93 |
Adial Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.8M | -$2.0M | -$2.0M | -$52.0M |
| Diluted EPS | -$2.00 | -$2.99 | -$1.48 | -$11.25 |
Adial Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.4M | $6.1M | $4.0M | $2.8M | $3.8M | $5.9M |
| Current Assets | $5.1M | $6.5M | $4.8M | $3.2M | $4.1M | $6.2M |
| Total Assets | $5.5M | $7.5M | $5.7M | $4.7M | $5.0M | $6.7M |
| Current Liabilities | $1.5M | $2.7M | $1.8M | $653,076 | $975,858 | $1.4M |
| Total Long-Term Debt | — | $29,088 | $29,088 | — | — | — |
| Total Liabilities | $1.5M | $4.0M | $2.5M | $653,076 | $975,858 | $1.4M |
| Shareholders' Equity | $4.0M | $3.5M | $3.3M | $4.1M | $4.1M | $5.3M |
Adial Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$7.6M | -$11.9M | -$11.2M | -$6.8M | -$6.9M | -$6.5M |
| Cash From Investing | -$350,000 | -$34,016 | — | $1.5M | — | $150,000 |
| Cash From Financing | $5.6M | $13.6M | $9.1M | $4.1M | $7.8M | $8.5M |
| Free Cash Flow | — | -$12.0M | -$11.3M | — | — | — |
Figures from Adial Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Adial Pharmaceuticals financials page for every line item.
Adial Pharmaceuticals Company Profile
| Ticker | ADIL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Charlottesville, Virginia |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001513525 |
Frequently Asked Questions
What was Adial Pharmaceuticals' revenue in fiscal 2025?
Adial Pharmaceuticals (ADIL) reported revenue of $0 for fiscal 2025.
What is Adial Pharmaceuticals' annual revenue history?
Adial Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Adial Pharmaceuticals' net income in fiscal 2025?
Adial Pharmaceuticals reported net income of -$8.0M for fiscal 2025.
What was Adial Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Adial Pharmaceuticals' diluted EPS was -$11.93 for fiscal 2025 (adjusted for any later stock splits).
What was Adial Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Adial Pharmaceuticals reported revenue of $0.
How many shares of Adial Pharmaceuticals are outstanding?
Adial Pharmaceuticals reported a weighted average of 4.6 million basic shares outstanding in 2026 Q2.
What is Adial Pharmaceuticals' market cap?
Based on its latest closing price, Adial Pharmaceuticals (ADIL) has a market capitalization of about $15.2M.
When does Adial Pharmaceuticals' fiscal year end?
Adial Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Adial Pharmaceuticals headquartered?
Adial Pharmaceuticals lists its business address in Charlottesville, Virginia in its SEC filings.